1. Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimers disease trial.
- Author
-
Molina-Henry, Doris, Raman, Rema, Liu, Andy, Langford, Oliver, Johnson, Keith, Shum, Leona, Glover, Crystal, Dhadda, Shobha, Irizarry, Michael, Jimenez-Maggiora, Gustavo, Braunstein, Joel, Yarasheski, Kevin, Venkatesh, Venky, West, Tim, Verghese, Philip, Rissman, Robert, Aisen, Paul, Grill, Joshua, and Sperling, Reisa
- Subjects
amyloid ,biomarker ,ethnicity ,plasma ,positron emission tomography ,race ,Aged ,Female ,Humans ,Male ,Alzheimer Disease ,Amyloid beta-Peptides ,Biomarkers ,Brain ,Ethnicity ,Positron-Emission Tomography ,Racial Groups - Abstract
INTRODUCTION: In trials of amyloid-lowering drugs for Alzheimers disease (AD), differential eligibility may contribute to under-inclusion of racial and ethnic underrepresented groups. We examined plasma amyloid beta 42/40 and positron emission tomography (PET) amyloid eligibility for the ongoing AHEAD Study preclinical AD program (NCT04468659). METHODS: Univariate logistic regression models were used to examine group differences in plasma and PET amyloid screening eligibility. RESULTS: Of 4905 participants screened at time of analysis, 1724 were plasma eligible to continue in screening: 13.3% Hispanic Black, 24.7% Hispanic White, 20.8% non-Hispanic (NH) Asian, 24.7% NH Black, and 38.9% NH White. Plasma eligibility differed across groups in models controlling for covariates (odds ratio from 1.9 to 4.0 compared to the NH White reference group, P
- Published
- 2024